| Literature DB >> 32613272 |
Joham Choque-Velasquez1,2,3, Julio Resendiz-Nieves4, Behnam Rezai Jahromi4, Szymon Baluszek5,6, Sajjad Muhammad4,7, Roberto Colasanti8,9, Juha Hernesniemi4,10.
Abstract
PURPOSE: Surgical series of pineal region gliomas are rarely available. Whereas it is a general assumption that the extent of surgical resection correlates with survival outcomes of intracranial gliomas; the impact of the microsurgical resection on the long-term outcomes of pineal gliomas has been questioned. We present a surgical series of pineal region gliomas with focus on the survival outcome analysis.Entities:
Keywords: Pineal region gliomas; extent of surgical resection; long-term outcomes; survival rate
Mesh:
Year: 2020 PMID: 32613272 PMCID: PMC7438290 DOI: 10.1007/s11060-020-03571-z
Source DB: PubMed Journal: J Neurooncol ISSN: 0167-594X Impact factor: 4.130
Adjuvant radiochemotherapy protocols for gliomas at HUH. Number of patients in parenthesis
| Adjuvant radiochemotherapy | |
|---|---|
| Pilocytic astrocytoma (10) | A giant tumor was initially treated with biopsy and radiotherapy in 1985, followed by brachytherapy in 1995, and multiple surgeries since 2000. The patient died 324 months after initial treatment. No other patient received adjuvant therapy. |
| Grade I-II Ependymoma (2) | 54 Gy (1.8 Gy/dia) after subtotal resection in one case. |
| Grade II Astrocytoma (1) | None, patient with complications died 3 months after complete resection. |
| Grade III Astrocytoma (2) | 20 Gy (10 Gy/dose) of stereotactic radiosurgery and unspecified chemotherapy* for a small 5 mm local recurrence of the tumor, 15 months after subtotal resection (initially suspected as totally resected tumor). The patient died 52 months after initial treatment. Fractionated radiation therapy* and temozolamide 150 mg/m2 (unspecified number of cycles) after partial resection of the tumor. The patient died 12 months after initial treatment. |
| Glioblastoma multiforme (2) | 54 Gy (1.8 Gy/dia) and temozolomide 150 mg/m2 (2 cycles) after subtotal resection of the tumor. More cycles of temozolamide were planned; however, the tumor progressed rapidly. The patient died 5 months after initial treatment. 36 Gy (3 Gy/dose) and temozolomide 150 mg/m2 (2 cycles) after complete resection of the tumor. More cycles of temozolamide were planned; however, the patient developed a pneumocystis infection and Eaton-Lambert syndrome. The patient died 9 months after initial treatment. |
*Unspecified in the patient records
Comparative analysis between the non diffuse glioma and diffuse glioma patients. For numeric variables, median (interquartile range)
| All | Nondiffuse Glioma | Diffuse Glioma | P value | Adjusted p-value | |
|---|---|---|---|---|---|
| Age in years | 26 (20–51) | 23 (4–33) | 26 (21–64) | 0.56 | 1 |
| Sex: males | 13 (76%) | 9 (75%) | 4 (80%) | 1 | 1 |
| Preoperative mRS (patients) | 2 (1), 3 (3), 4 (7), 5 (6) | 2 (1), 3 (2), 4 (5), 5 (4) | 3 (1), 4 (2), 5 (2) | 0.79 | 1 |
| Hydrocephalus | 15 (88%) | 11 (92%) | 4 (80%) | 0.52 | 1 |
| Preliminary shunt | 8 (53%) | 5 (45%) | 3 (75%) | ||
| Direct surgery | 6 (40%) | 5 (45%) | 1 (25%) | ||
| ETV | 1 (7%) | 1 (9%) | 0 | ||
| Tumor size in mm | |||||
| Anterior–posterior | 30 (25–38) | 29 (26–55) | 26 (21–35) | 0.40 | 1 |
| Cranio-caudal | 22 (19–30) | 26 (20–33) | 20 (19–26) | 0.64 | 0.9 |
| Axial-wide | 25 (22–36) | 39 (25–50) | 22 (22–36) | 0.53 | 1 |
| Surgical approach | 1 | 1 | |||
| SCIT | 16 (94%) | 11 (92%) | 5 (100%) | ||
| OTT | 1 (6%) | 1 (8%) | 0 | ||
| Extent of resection | |||||
| GTR | 9 (53%) | 7 (58%) | 2 (40%) | 0.62 | 1 |
| STR | 6 (35%) | 4 (33%) | 2 (40%) | 1 | 1 |
| PR | 2 (12%) | 1 (8%) | 1 (20%) | 0.52 | 1 |
| Immediate mRS (patients) | 1 (4), 2 (6), 3 (4), 4 (3) | 1 (3), 2 (4), 3 (4), 4 (1) | 1 (1), 2 (2), 4 (2) | 0.68 | 0.9 |
| Follow-up in months | 83 (52–148) | 139 (136–231) | 9 (5–12) | ||
| 5-year survival | 33% | 100% | 0 | < | |
| 10-year survival | 39% | 100% | 0 | < | |
| Final mRS (patients) | 0 (3), 1 (6), 2 (1), 3 (1), 6 (6) | 0 (3), 1 (6), 2 (1), 3 (1), 6 (1) | 6 (5) |
Values with statistical significance in bold
ETV external third ventriculostomy, GTR gross total resection mRS modified Rankin scale, PR partial resection, OTT occipital transtentorial approach, SCIT supracerebellar infratentorial approach, STR subtotal resection
Fig. 1Preoperative, immediate (at hospital discharge of the patient), and last available postoperative functional status of nondiffuse low grade glioma (blue), and diffuse high-grade glioma (red) patients. mRS, modified Rankin Scale
Fig. 2Kaplan–Meier curve comparing survival rates between diffuse and non-diffuse gliomas. p < 0.001 in the likelihood ratio Cox model (Cox LR). In dashed lines, 0.5 of survival rate
Fig. 3Kaplan–Meier curve for the analysis of extent of surgical resection and survival rates of pineal region gliomas; GTR, gross total resection. p = 0.6 in the likelihood ratio Cox model (Cox LR). In dashed lines, 0.5 of survival rate
Fig. 4Multivariate Cox model analysis for the mortality of pineal region glioma patients. GTR, gross total resection; mRS1, preoperative modified Rankin scale; WHO_Grade, World Health Organization grade diagnosis
Characteristics of the pineal region glioma in children. For numeric variables, median (interquartile range)
| All | ≥ 20-year old | ≤ 5-year old | P value | Adjusted p-value | |
|---|---|---|---|---|---|
| Age in years | 26 (20–51) | 33 (23–54) | 2.5 (2 – 3.3) | ||
| Sex: males | 13 (76%) | 10 (77%) | 3 (75%) | 1 | 1 |
| Preoperative mRS (patients) | 2 (1), 3 (3), 4 (7), 5 (6) | 2 (1), 3 (2), 4 (5), 5 (5) | 3 (1), 4 (2), 5 (1) | 0.79 | 1 |
| Hydrocephalus | 15 (88%) | 11 (85%) | 4 (100%) | 1 | 1 |
| Preliminary shunt | 8 (53%) | 5 (39%) | 3 (75%) | ||
| Direct surgery | 6 (40%) | 5 (39%) | 1 (25%) | ||
| ETV | 1 (7%) | 1 (8%) | 0 | ||
| Diagnosis | 1 | 1 | |||
| Non diffuse glioma | 12 (71%) | 9 (70%) | 3 (75%) | ||
| Diffuse glioma | 5 (29%) | 4 (31%) | 1 (25%) | ||
| Tumor size in mm | |||||
| Anterior–posterior | 30 (25–38) | 26 (23–30) | 47 (37–64) | ||
| Cranio-caudal | 22 (19–30) | 20 (18–28) | 31 (26–37) | 0.06 | 0.32 |
| Axial-wide | 25 (22–36) | 25 (22–30) | 44 (37–51) | ||
| Surgical approach | 1 | 1 | |||
| SCIT | 16 (94%) | 12 (92%) | 4 (100%) | ||
| OTT | 1 (6%) | 1 (8%) | 0 | ||
| Extent of resection | |||||
| GTR | 9 (53%) | 7 (54%) | 2 (50%) | 1 | 1 |
| STR | 6 (35%) | 5 (39%) | 1 (25%) | 1 | 1 |
| PR | 2 (12%) | 1 (8%) | 1 (25%) | 0.43 | 1 |
| Immediate mRS (patients) | 1 (4), 2 (6), 3 (4), 4 (3) | 1 (4), 2 (5), 3 (2), 4 (2) | 2 (1), 3 (2), 4 (1) | 0.16 | 0.64 |
| Follow-up in months | 83 (52–148) | 83 (52 – 148) | 96 (40–185) | 0.96 | 1 |
| Tumor at the last MRI | 47% | 46% | 50% | 1 | 1 |
| Overall mortality | 35% | 31% | 50% | 0.58 | 1 |
| Final mRS (patients) | 0 (3), 1 (6), 2 (1), 3 (1), 6 (6) | 0 (2), 1 (6), 2 (1), 6 (4) | 0 (1), 3 (1), 6 (2) | 0.55 | 1 |
Values with statistical significance in bold
ETV external third ventriculostomy, GTR gross total resection, mRS modified Rankin scale, PR partial resection, OTT occipital transtentorial approach, SCIT supracerebellar infratentorial approach, STR subtotal resection